The majority of these patients were already on an ACEI/ARB.
The results of the TOPCAT trial indicate that spironolactone is not superior to placebo in improving CV outcomes in patients with HFpEF. Benefit of spironolactone compared with placebo was similar to the overall population (p for interaction = 0.38).
These patients had the worst prognosis among the patients enrolled (HR 2.10, 95% CI 1.26-3.5, p = 0.004). HFpEF phenotype suggestive of amyloid: Among 590 patients with detailed echocardiography data, 23% had echo phenotype suggestive of amyloid (septal thickness ≥1.2 cm, s’ velocity ≤6 cm/s). placebo based on gender: women, 25.1% vs. Women were older with fewer comorbidities. There was no effect modification by AF for the primary endpoint for spironolactone vs. Post-randomization AF occurred in 6.3% of patients and was associated with an increased early risk of the primary outcome (HR 2.32, 95% CI 1.59-3.40, p < 0.0001). Patients with any history/prevalent AF had numerically higher incidence of the primary endpoint (12.1% vs. These patients had higher left atrial volumes than patients without AF. Influence of AF: AF was common, either based on ECG at enrollment (25%) or based on history (18%). 9.1%, p 2 upper limit of normal were both significantly higher in the spironolactone arm. CHF hospitalizations were lower (12.0% vs. 5 events, p = 0.48) were similar between the two arms. p = 0.35) and aborted cardiac arrest (3 vs. Individual components including CV mortality (9.3% vs. The primary endpoint of CV death, chronic HF (CHF) hospitalization, or resuscitated cardiac arrest over 6 years was similar between the spironolactone and placebo arms (18.6% vs. Close to 29% of patients were enrolled into stratum II (elevated B-type natriuretic peptide /N-terminal proBNP). Coexisting coronary artery disease was noted in 59% and atrial fibrillation (AF) in 35%. Hypertension was present in 92% of patients, with median blood pressure (BP) of 130/80 mm Hg. The baseline EF was 56%, 52% were female, and nearly two-thirds of the patients had New York Heart Association (NYHA) class II symptoms. Baseline characteristics were fairly similar between the two arms. Concomitant Medications:Īngiotensin-converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) (84%), diuretic (82%), and statin (53%)Ī total of 3,445 patients were randomized at 233 sites in six countries: 1,722 to spironolactone and to 1,723 to placebo. Spironolactone was initiated at a dose of 15 mg/day and uptitrated to a maximum of 45 mg daily during the first 4 months of randomization. Patients were randomized in 1:1 fashion to either spironolactone versus placebo.
If you are located within the United States and believe our view of your activity is unwarranted, please feel free to email us at "blocked at ". As such, our business model focuses on connecting and servicing buyers and sellers that are located only in the US. Our database is over 17 million businesses that are solely located in the United States. This is a breach of our Terms Of Use.Ģ.) The IP is part of a virtual private network (VPN) to mask your actual IP, or your IP was masked and served a proxy IP.ģ.) You are located outside of the United States. Sorry, but we are currently blocking access to our site.ġ.) We have detected an unusual amount of improper or excessive behavior such as using our site to compile business lists, company information, accumulate sales leads, etc.